Glen Eagle Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Glen Eagle Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-250	Closed	-$538	–	1013
2020 Q3	$538	Hold	250	–	–	﹤0.01%	880
2020 Q2	$290	Hold	250	–	–	﹤0.01%	883
2020 Q1	$230	Hold	250	–	–	﹤0.01%	826
2019 Q4	$395	Buy	250 +240	+2,400%	+$227	﹤0.01%	864
2019 Q3	$8	Hold	10	–	–	﹤0.01%	820
2019 Q2	$9	Hold	10	–	–	﹤0.01%	795
2019 Q1	$10	Hold	10	–	–	﹤0.01%	738
2018 Q4	$7	Hold	10	–	–	﹤0.01%	720
2018 Q3	$22	Hold	10	–	–	﹤0.01%	710
2018 Q2	$50	Hold	10	–	–	﹤0.01%	687
2018 Q1	$39	Hold	10	–	–	﹤0.01%	678
2017 Q4	$27	Hold	10	–	–	﹤0.01%	639
2017 Q3	$32	Buy	+10	New	+$33	﹤0.01%	632

Other funds holding CTIC

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management

Verition Fund Management Greenwich, Connecticut $10.3B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return